NO324880B1 - Tuberkulose-antigener og fusjonsproteiner omfattende disse, DNA som koder for antigenene og ekspresjonsvektorer og vertsceller omfattende dette DNA, samt farmasoytiske sammensetninger og vaksiner for immunoterapi og diagnose av tuberkulose. - Google Patents
Tuberkulose-antigener og fusjonsproteiner omfattende disse, DNA som koder for antigenene og ekspresjonsvektorer og vertsceller omfattende dette DNA, samt farmasoytiske sammensetninger og vaksiner for immunoterapi og diagnose av tuberkulose. Download PDFInfo
- Publication number
- NO324880B1 NO324880B1 NO19995689A NO995689A NO324880B1 NO 324880 B1 NO324880 B1 NO 324880B1 NO 19995689 A NO19995689 A NO 19995689A NO 995689 A NO995689 A NO 995689A NO 324880 B1 NO324880 B1 NO 324880B1
- Authority
- NO
- Norway
- Prior art keywords
- tuberculosis
- seq
- polypeptide
- dna
- sequences
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 117
- 239000000427 antigen Substances 0.000 title claims abstract description 84
- 102000036639 antigens Human genes 0.000 title claims abstract description 84
- 108091007433 antigens Proteins 0.000 title claims abstract description 84
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 26
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 26
- 229960005486 vaccine Drugs 0.000 title claims abstract description 21
- 239000013604 expression vector Substances 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 16
- 238000003745 diagnosis Methods 0.000 title description 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 171
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 159
- 229920001184 polypeptide Polymers 0.000 claims abstract description 140
- 108020004414 DNA Proteins 0.000 claims abstract description 38
- 230000002163 immunogen Effects 0.000 claims abstract description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 22
- 102000053602 DNA Human genes 0.000 claims abstract description 16
- 239000002671 adjuvant Substances 0.000 claims abstract description 10
- 241000588724 Escherichia coli Species 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 239000003623 enhancer Substances 0.000 claims abstract description 7
- 230000015788 innate immune response Effects 0.000 claims abstract description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 40
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 230000001681 protective effect Effects 0.000 claims description 11
- 230000036039 immunity Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000004071 biological effect Effects 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 210000004927 skin cell Anatomy 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 26
- 238000006467 substitution reaction Methods 0.000 abstract description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 4
- 239000013598 vector Substances 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 3
- 230000004048 modification Effects 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 49
- 238000000034 method Methods 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 27
- 239000002299 complementary DNA Substances 0.000 description 26
- 108010074328 Interferon-gamma Proteins 0.000 description 20
- 230000035755 proliferation Effects 0.000 description 18
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 12
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 12
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 12
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 12
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 12
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 12
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 12
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 12
- 101000768804 Micromonospora olivasterospora Uncharacterized 10.9 kDa protein in fmrO 5'region Proteins 0.000 description 12
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 12
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 12
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 12
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 12
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 12
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 108700026244 Open Reading Frames Proteins 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 9
- 102000008070 Interferon-gamma Human genes 0.000 description 8
- 230000006052 T cell proliferation Effects 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000014828 interferon-gamma production Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 229960003130 interferon gamma Drugs 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 6
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 6
- 101000933555 Bacillus subtilis (strain 168) Biofilm-surface layer protein A Proteins 0.000 description 6
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 6
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 6
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 6
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 6
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 6
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 6
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 6
- 101000773449 Sinorhizobium fredii (strain NBRC 101917 / NGR234) Uncharacterized HTH-type transcriptional regulator y4sM Proteins 0.000 description 6
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 6
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 6
- 101000987243 Streptomyces griseus Probable cadicidin biosynthesis thioesterase Proteins 0.000 description 6
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 6
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 6
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 6
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 6
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000019734 interleukin-12 production Effects 0.000 description 6
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 5
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 5
- 230000016396 cytokine production Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229940117681 interleukin-12 Drugs 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000005951 type IV hypersensitivity Effects 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001400 expression cloning Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 1
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical group [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100037714 Male-specific lethal 1 homolog Human genes 0.000 description 1
- 101710119089 Male-specific lethal 1 homolog Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102100023870 YLP motif-containing protein 1 Human genes 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- -1 hexafluorophosphate Chemical compound 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 101150023079 mpt83 gene Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000004492 positive regulation of T cell proliferation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85938197A | 1997-05-20 | 1997-05-20 | |
| US09/073,010 US6613881B1 (en) | 1997-05-20 | 1998-05-05 | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
| PCT/US1998/010407 WO1998053075A2 (en) | 1997-05-20 | 1998-05-20 | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO995689D0 NO995689D0 (no) | 1999-11-19 |
| NO995689L NO995689L (no) | 2000-01-18 |
| NO324880B1 true NO324880B1 (no) | 2007-12-27 |
Family
ID=26754016
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19995689A NO324880B1 (no) | 1997-05-20 | 1999-11-19 | Tuberkulose-antigener og fusjonsproteiner omfattende disse, DNA som koder for antigenene og ekspresjonsvektorer og vertsceller omfattende dette DNA, samt farmasoytiske sammensetninger og vaksiner for immunoterapi og diagnose av tuberkulose. |
| NO20075900A NO20075900L (no) | 1997-05-20 | 2007-11-15 | Forbindelser for immunterapi og diagnose av tuberkulose og metoder for deres anvendelse |
| NO20075902A NO20075902L (no) | 1997-05-20 | 2007-11-15 | Forbindelser for immunoterapi og diagnose av turberkolose og metoder for deres anvendelse |
| NO20075901A NO20075901L (no) | 1997-05-20 | 2007-11-15 | Forbindelser for immunterapi og diagnose av tuberkolose og metoder for deres anvendelse |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075900A NO20075900L (no) | 1997-05-20 | 2007-11-15 | Forbindelser for immunterapi og diagnose av tuberkulose og metoder for deres anvendelse |
| NO20075902A NO20075902L (no) | 1997-05-20 | 2007-11-15 | Forbindelser for immunoterapi og diagnose av turberkolose og metoder for deres anvendelse |
| NO20075901A NO20075901L (no) | 1997-05-20 | 2007-11-15 | Forbindelser for immunterapi og diagnose av tuberkolose og metoder for deres anvendelse |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6613881B1 (hu) |
| EP (4) | EP2270170B1 (hu) |
| JP (4) | JP4162155B2 (hu) |
| KR (4) | KR100652513B1 (hu) |
| AT (1) | ATE420180T1 (hu) |
| AU (1) | AU742751B2 (hu) |
| BR (1) | BR9809445A (hu) |
| CA (2) | CA2783134A1 (hu) |
| CZ (2) | CZ303194B6 (hu) |
| DE (1) | DE69840449D1 (hu) |
| DK (1) | DK1012293T3 (hu) |
| ES (1) | ES2321039T3 (hu) |
| HU (1) | HU226520B1 (hu) |
| IL (2) | IL133056A0 (hu) |
| NO (4) | NO324880B1 (hu) |
| NZ (1) | NZ501310A (hu) |
| PL (1) | PL191121B1 (hu) |
| PT (1) | PT1012293E (hu) |
| TR (1) | TR200000115T2 (hu) |
| WO (1) | WO1998053075A2 (hu) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
| US6290969B1 (en) * | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6592877B1 (en) * | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6982085B2 (en) | 1997-04-02 | 2006-01-03 | Statens Serum Institut | TB diagnostic based on antigens from M. tuberculosis |
| US7037510B2 (en) | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
| PT1003850E (pt) * | 1997-06-06 | 2009-08-13 | Dynavax Tech Corp | Inibidores da actividade de sequências de adn imunoestimulantes |
| EP1029053A1 (en) * | 1997-11-10 | 2000-08-23 | Statens Seruminstitut | Nucleic acid fragments and polypeptide fragments derived from mycobacterium tuberculosis |
| DE69941545D1 (de) | 1998-11-04 | 2009-11-26 | Isis Innovation | Tuberkulose diagnose test |
| US20030027774A1 (en) * | 1999-03-18 | 2003-02-06 | Ronald C. Hendrickson | Tuberculosis antigens and methods of use therefor |
| US8143386B2 (en) * | 1999-04-07 | 2012-03-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| CA2378763A1 (en) | 1999-07-13 | 2001-01-18 | Statens Serum Institut | Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosis esat-6 gene family |
| WO2001024820A1 (en) | 1999-10-07 | 2001-04-12 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US6316205B1 (en) | 2000-01-28 | 2001-11-13 | Genelabs Diagnostics Pte Ltd. | Assay devices and methods of analyte detection |
| AU2001241738A1 (en) * | 2000-02-25 | 2001-09-03 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| EP1278769A2 (en) * | 2000-04-19 | 2003-01-29 | Statens Serum Institut | Tuberculosis antigens and methods of use thereof |
| SI1542732T1 (sl) * | 2000-06-20 | 2010-01-29 | Corixa Corp Csc The United Sta | Fuzijski proteini Mycobacterium tuberculosis |
| US7026465B2 (en) * | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
| US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
| WO2005118884A1 (en) * | 2004-05-28 | 2005-12-15 | The United States Of America As Represented By The Secretary Of The Navy | A method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines |
| US8475735B2 (en) * | 2004-11-01 | 2013-07-02 | Uma Mahesh Babu | Disposable immunodiagnostic test system |
| SG159555A1 (en) * | 2004-11-16 | 2010-03-30 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
| CA2606962A1 (en) * | 2005-04-29 | 2006-11-09 | Fusion Antibodies Limited | Assays for diagnosis of tuberculosis and uses thereof |
| CN101365714A (zh) | 2005-07-01 | 2009-02-11 | 福赛特儿童口腔医院 | 结核抗原的检测分析及疫苗 |
| WO2007041539A1 (en) * | 2005-09-30 | 2007-04-12 | Transcutaneous Technologies, Inc. | Iontophoresis apparatus and method for the diagnosis of tuberculosis |
| BRPI0708912B8 (pt) | 2006-03-14 | 2021-07-27 | Univ Oregon Health & Science | métodos in vitro para detecção de mycobacterium tuberculosis e de células t expressando cd8 que especificamente reconhecem seq id no: 11 em um indivíduo |
| KR20110060891A (ko) | 2008-07-25 | 2011-06-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 신규한 조성물 및 방법 |
| PT2315773T (pt) * | 2008-07-25 | 2016-11-23 | Glaxosmithkline Biologicals Sa | Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente |
| HUE039159T2 (hu) | 2008-07-25 | 2018-12-28 | Glaxosmithkline Biologicals Sa | Tuberkulózis Rv2386c protein, ezt tartalmazó készítmények és ezek alkalmazása |
| KR20120129927A (ko) | 2010-01-27 | 2012-11-28 | 글락소 그룹 리미티드 | 변형된 투베르쿨로시스 항원 |
| GB201012072D0 (en) | 2010-07-19 | 2010-09-01 | Sec Dep For Environment Food A | Diagnostic reagents |
| EP3928715A1 (en) | 2011-06-19 | 2021-12-29 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
| JP7344631B2 (ja) | 2015-02-09 | 2023-09-14 | アボゲン， インコーポレイティド | サンプル収集関連応用、分析および診断のためのデバイス、溶液および方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4689397A (en) | 1985-08-12 | 1987-08-25 | Scripps Clinic And Research Foundation | Synthetic polypeptides for detecting mycobacterial infections |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4879213A (en) | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
| US4976958A (en) * | 1987-02-26 | 1990-12-11 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
| US4952395A (en) | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
| US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US5330754A (en) | 1992-06-29 | 1994-07-19 | Archana Kapoor | Membrane-associated immunogens of mycobacteria |
| JPH09510866A (ja) * | 1993-12-23 | 1997-11-04 | アグリサーチ ニュージーランド パストラル アグリカルチャー リサーチ インスティテュート，リミテッド | ミコバクテリア毒力因子およびその同定のための方法 |
| AU706367B2 (en) * | 1995-03-13 | 1999-06-17 | Astra Aktiebolag | New DNA molecules |
| US6290969B1 (en) * | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| DE69637879D1 (de) | 1995-09-01 | 2009-04-30 | Corixa Corp | Verbindungen und Verfahren zur Immuntherapie und Diagnose von Tuberkulose |
| WO1997009429A2 (en) | 1995-09-01 | 1997-03-13 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| EP0934415A2 (en) * | 1996-10-11 | 1999-08-11 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
-
1998
- 1998-05-05 US US09/073,010 patent/US6613881B1/en not_active Expired - Fee Related
- 1998-05-20 IL IL13305698A patent/IL133056A0/xx unknown
- 1998-05-20 NZ NZ501310A patent/NZ501310A/en not_active IP Right Cessation
- 1998-05-20 AT AT98924827T patent/ATE420180T1/de active
- 1998-05-20 EP EP10174426.6A patent/EP2270170B1/en not_active Expired - Lifetime
- 1998-05-20 PT PT98924827T patent/PT1012293E/pt unknown
- 1998-05-20 BR BR9809445-9A patent/BR9809445A/pt not_active Application Discontinuation
- 1998-05-20 KR KR1019997010775A patent/KR100652513B1/ko not_active IP Right Cessation
- 1998-05-20 ES ES98924827T patent/ES2321039T3/es not_active Expired - Lifetime
- 1998-05-20 EP EP98924827A patent/EP1012293B1/en not_active Expired - Lifetime
- 1998-05-20 TR TR2000/00115T patent/TR200000115T2/xx unknown
- 1998-05-20 CA CA2783134A patent/CA2783134A1/en not_active Abandoned
- 1998-05-20 KR KR1020067010257A patent/KR100893118B1/ko not_active IP Right Cessation
- 1998-05-20 HU HU0003402A patent/HU226520B1/hu not_active IP Right Cessation
- 1998-05-20 JP JP55063498A patent/JP4162155B2/ja not_active Expired - Fee Related
- 1998-05-20 KR KR1020087007618A patent/KR100924475B1/ko not_active IP Right Cessation
- 1998-05-20 CZ CZ20080478A patent/CZ303194B6/cs not_active IP Right Cessation
- 1998-05-20 DK DK98924827T patent/DK1012293T3/da active
- 1998-05-20 KR KR1020077003582A patent/KR100909640B1/ko not_active IP Right Cessation
- 1998-05-20 EP EP08172265A patent/EP2172551A3/en not_active Withdrawn
- 1998-05-20 PL PL337330A patent/PL191121B1/pl not_active IP Right Cessation
- 1998-05-20 CZ CZ0410099A patent/CZ300866B6/cs not_active IP Right Cessation
- 1998-05-20 DE DE69840449T patent/DE69840449D1/de not_active Expired - Lifetime
- 1998-05-20 AU AU76907/98A patent/AU742751B2/en not_active Ceased
- 1998-05-20 EP EP10174425A patent/EP2248900B1/en not_active Expired - Lifetime
- 1998-05-20 WO PCT/US1998/010407 patent/WO1998053075A2/en active Application Filing
- 1998-05-20 CA CA002290774A patent/CA2290774A1/en not_active Abandoned
-
1999
- 1999-11-19 NO NO19995689A patent/NO324880B1/no not_active IP Right Cessation
- 1999-11-19 IL IL133056A patent/IL133056A/en not_active IP Right Cessation
-
2007
- 2007-11-15 NO NO20075900A patent/NO20075900L/no not_active Application Discontinuation
- 2007-11-15 NO NO20075902A patent/NO20075902L/no not_active Application Discontinuation
- 2007-11-15 NO NO20075901A patent/NO20075901L/no not_active Application Discontinuation
-
2008
- 2008-03-18 JP JP2008070066A patent/JP4764445B2/ja not_active Expired - Fee Related
- 2008-03-18 JP JP2008070073A patent/JP4759011B2/ja not_active Expired - Fee Related
- 2008-03-18 JP JP2008070069A patent/JP4759010B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4764445B2 (ja) | 結核の免疫治療および診断のための化合物およびそれらの使用方法 | |
| CA2653566C (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
| US7989605B2 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
| US8084042B2 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
| WO1997009428A9 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
| ES2445209T3 (es) | Compuestos para inmunoterapia y diagnóstico de la tuberculosis y métodos de su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |